Aspira Pathlab board approves ₹65 crore right issue

1 min read | Published on 12 Sept 2026, 04:51 PM |Updated on 12 Sept 2026, 04:51 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Aspira Pathlab board approves right issue of up to ₹65 crore
Funds to be raised via equity or convertible instruments
Issue subject to shareholder and regulatory approvals
Right Issue Committee formed to finalize terms and record date

*this image is generated using AI for illustrative purposes only.

The board of directors of Aspira Pathlab & Diagnostics Limited approved a right issue to raise up to ₹65 crore during its meeting held on September 12, 2026. The capital raise aims to strengthen the company’s financial position through equity or convertible instruments.

The issuance is subject to necessary approvals from shareholders and regulatory bodies, including compliance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and the SEBI Listing Regulations. The company will determine the record date, issue price, and entitlement ratio in due course.

Committee Formation

To oversee the process, the board constituted a Right Issue Committee responsible for finalizing terms and conditions. The committee will also appoint intermediaries and manage other related matters for the issuance.

Name	Role
Mr. Nikunj Velji Mange	Chairman
Mr. Vaibhav Odhekar	Member
Mrs. Kiran Raghavendra Awasthi	Member
Mr. Balkrishna Subhash Talawadekar	Member

Regulatory Compliance

The decision was taken under Regulation 30 of the SEBI (LODR) Regulations, 2015. The meeting commenced at 4:00 pm and concluded at 4:30 pm. Managing Director Nikunj Velji Mange signed the disclosure.

Historical Stock Returns for Aspira Pathlab

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.47%	+2.15%	-9.35%	+67.79%	+46.45%	0.0%

How will the ₹65 crore capital infusion specifically impact Aspira Pathlab's expansion plans or debt reduction strategy?

What is the expected timeline for shareholder approval and finalization of the issue price and entitlement ratio?

Could the right issue lead to significant dilution for existing shareholders, and how might this affect the stock's short-term valuation?

Aspira Pathlab

View Company Insights

View All News

Aspira Pathlab promoter Jay Arvind Bhanushali acquires 74 shares

1 min read | Published on 12 Sept 2026, 01:45 PM |Updated on 12 Sept 2026, 01:45 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Promoter Jay Arvind Bhanushali acquired 74 equity shares in Aspira Pathlab via open market on September 10, 2026
The acquisition leaves his total stake unchanged at 7.25% of the voting capital
His total holding increased from 7,46,377 to 7,46,451 shares
The disclosure was filed with the BSE on September 11, 2026, under SEBI SAST Regulations

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab promoter Jay Arvind Bhanushali acquired 74 equity shares in the company through the open market on September 10, 2026. The transaction was disclosed to the BSE on September 11, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The acquisition represents a negligible change in his overall stake. Bhanushali held 7,46,377 shares, constituting 7.25% of the total voting capital, prior to this transaction. Following the purchase, his total holding stands at 7,46,451 shares, maintaining the same 7.25% stake.

What the Numbers Show

The acquisition of 74 shares is immaterial relative to Bhanushali's existing position of over 7.4 lakh shares. The transaction does not alter the promoter's voting power or control structure within Aspira Pathlab & Diagnostics Ltd.

Transaction Details

Metric	Value
Acquirer	Jay Arvind Bhanushali
Shares Acquired	74
Mode	Open Market
Date of Acquisition	September 10, 2026
Stake Before	7.25% (7,46,377 shares)
Stake After	7.25% (7,46,451 shares)

The company’s total equity share capital remains at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each. There were no encumbrances, warrants, or convertible securities involved in this transaction.

Historical Stock Returns for Aspira Pathlab